For most of the single-stock leverage era, the products only pointed one way. Somebody has quietly stopped believing that, and the evidence is sitting in the latest batch of listings.
Four new leveraged single-stock funds arrived from one issuer. Three of them are shorts. The fourth, the only bullish product in the set, is strapped to a company whose quarterly revenue would not cover a mid-sized marketing budget.
Start with the largest name, because it is the strangest inclusion.
Meta Platforms is one of the most heavily analysed, most widely held, most liquid equities in existence. If you want to bet against it, the world has already provided you with a listed options market of extraordinary depth, a securities lending market that functions perfectly well, and an entire ecosystem of professionals who will happily take the other side.
And yet here is a fund seeking minus two hundred percent of Meta's daily move, with a daily reset, aimed at investors who apparently need the shorting done for them. The pitch is convenience, and convenience is a real product. Fine.
The detail worth pausing on is that this is the issuer's first Meta product of any kind. There is no long version. There never was one.
Look across the rest of the shelf and that turns out to be the house rule rather than an oversight. Amazon, Oracle and Tesla are all available as inverse products with no bullish sibling. Nvidia is short-only too. Every mega-cap on the platform exists purely as something to bet against.
Which is a quietly remarkable position for a product line to hold. If you want double-speed exposure to a small-cap quantum computing company or a bitcoin miner, the shelf will happily sell you optimism. If you want it on the largest companies in the world, the only direction on offer is down.
This one made me put my coffee down.
AXT makes indium phosphide substrates, the unglamorous wafer material sitting underneath the high-speed optical links that make AI data centres possible. It has been, by some measures, the single best-performing stock in the American market over a twelve-month window, up more than twentyfold. Gross margin has travelled from the single digits to the mid-forties. It posted record substrate revenue and returned to quarterly profitability. Nothing about the operating business looks like a short.
The detail that elevates this from odd to genuinely interesting is that the same issuer already runs a two times long product on the same stock. So the shelf now offers both directions on one small-cap semiconductor materials company, at double speed, resetting daily.
That is not a house view. That is a toll booth. The issuer is not betting on AXT going up or down; it is betting that people will keep arguing about it, loudly and with borrowed conviction. Which, on the evidence, is the more reliable trade.
Now put the two shorts side by side and the picture gets better.
Coherent is AXT's customer. The two companies signed a multi-year wafer supply agreement, with Coherent making a substantial advance payment to fund AXT's capacity expansion. That is about as bound together as two listed companies get: one has pre-paid for the other's output, and both are levered to the same optical build-out.
Both have now been handed a two-times inverse product, in the same batch, by the same issuer. Coherent's two-times long has been trading for a while, as AXT's has, so both halves of the supply chain now carry a matched pair. Whichever way the optical build-out resolves, the shelf is positioned to sell somebody the trade twice.
Whatever you think of the underlying view, there is something admirably complete about shorting a supply chain from both ends simultaneously. Should the AI optics story crack, this batch has you covered twice over. Should it not, you own two products decaying in tandem for precisely the same reason. Correlation is a feature right up until it is a bill.
And then, the sole long.
Lightwave Logic has spent years developing electro-optic polymer modulators, a technology that, if it works at scale, addresses a genuine bottleneck in optical interconnects. The engineering story is real. Several Tier 1 customers have advanced into late-stage prototype programmes. The balance sheet holds close to a hundred million dollars in cash against no debt, which buys the runway to reach a production ramp.
What it does not yet have is revenue. Quarterly sales are a five-figure number. The quarterly loss is a seven-figure number. The gap between those two facts is the entire investment case, and it will be resolved by engineering milestones and customer qualification cycles measured in quarters and years.
This one, notably, arrived without an inverse twin. No short version, no matched pair, no ability to take the other side at double speed. The only company in the batch you cannot bet against through this shelf is the one still waiting for its first meaningful sale.
So the inverse exposure has been aimed at two profitable, contracted, record-setting suppliers and a trillion-dollar advertising business, while the sole bullish product sits on the pre-revenue optionality play and stands unopposed. I have read that back several times. It still says what I think it says.
Something completely different, and completely Swiss.
This is an open-ended tracker certificate on the Global Currency Macro Index, collateralised through a triparty arrangement, offering exposure to an actively managed FX strategy built around central bank policy divergence, rate differentials and currency momentum. Minimum entry is modest. It is publicly offered in Switzerland. There is no capital protection.
Read that again slowly, because there is a lovely tension in it. It is a tracker certificate, which implies passive replication of an index. The index is actively managed, and it is the issuer's own. What you are buying, in substance, is a discretionary macro book with an index rulebook wrapped around it and a ticker bolted on the front.
I want to be clear that this is not a criticism. Currency markets turn over trillions of dollars a day and macro dispersion has been genuinely wide, which is exactly the environment in which discretionary FX ought to earn its fee. The structure is also, in fairness, more transparent and more collateralised than the private mandate it replaces. It is simply worth knowing that the word "index" in a product name now covers a very wide range of activities, some of which involve a human being making a decision about the yen before lunch.
Its stablemate, incidentally, is a ten-year note paying a fixed double-digit coupon out of a segregated cell. The house has range.
Landing in the same batch, two funds that could not be further from a daily reset.
Zevenbergen is a high-conviction growth manager of the old school: concentrated, patient, willing to look wrong for extended periods, running money for decades rather than sessions. Its two strategies have now arrived on an exchange, brought across from the mutual fund world with the portfolios and managers intact.
The contrast with the rest of the batch is almost too neat. On one side, four products explicitly labelled as short-term trading vehicles, whose own documentation asks investors to monitor them actively and warns that holding them for longer than a day produces something other than the advertised exposure. On the other, two funds whose entire proposition is that you should stop looking at the screen for five years.
Same wrapper. Same exchange. Same batch of paperwork. Holding periods separated by roughly three orders of magnitude.
Which brings me, as it so often does, to the least interesting product in the file.
This one takes your US dollars and puts them in high-interest deposit accounts. That is the strategy in full. No leverage, no inverse exposure, no daily reset, no index rulebook, no collateral agent, no polymer modulators, no supply agreement, no conviction of any kind. The management fee is zero.
It is a savings account with a ticker, listed so that Canadian investors can hold cash inside a brokerage account without the indignity of a wire transfer. It will never appear in a product-launch press release with the words "first to market" in it, and nobody will ever describe it as an expression of a high-conviction view.